Int J Stomatol ›› 2020, Vol. 47 ›› Issue (6): 706-710.doi: 10.7518/gjkq.2020107

• Reviews • Previous Articles     Next Articles

Research progress of host modulation therapy in the treatment of periodontal diseases

Chen Liang(),Ding Yi,Meng Shu()   

  1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Periodontics, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2020-03-05 Revised:2020-07-10 Online:2020-11-01 Published:2020-11-06
  • Contact: Shu Meng;
  • Supported by:
    National Key Basic Research and Development Program (973 Program)(2013CBA-01705-1)


Host modulation therapy (HMT) is a therapeutic concept that treats inflammatory diseases by modulating host immune inflammatory responses to reduce tissue destruction. HMT has been used to treat osteoporosis and arthritis, and its application in stomatology has attracted widespread attention in recent years. This article reviews the current research progress of host-modulating drugs in the field of periodontal therapy, mainly including tetracycline drugs, non-steroidal- anti-inflammatory drugs, bisphosphonates, pro-inflammatory cytokine antagonists, and lipoxins.

Key words: host modulation therapy, periodontal diseases, sub-antimicrobial dose doxycycline, chemically modified tetracycline, lipoxins

CLC Number: 

  • R781.4

[1] Preshaw PM. Host response modulation in perio-dontics[J]. Periodontol 2000, 2008,48:92-110.
doi: 10.1111/j.1600-0757.2008.00252.x pmid: 18715360
[2] Harvey JD. Periodontal microbiology[J]. Dent Clin N Am, 2017,61(2):253-269.
doi: 10.1016/j.cden.2016.11.005 pmid: 28317565
[3] Cotts KG, Cifu AS. Treatment of osteoporosis[J]. JAMA, 2018,319(10):1040-1041.
pmid: 29536084
[4] Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid arthritis: a brief overview of the treatment[J]. Med Princ Pract, 2018,27(6):501-507.
doi: 10.1159/000493390 pmid: 30173215
[5] Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review[J]. JAMA, 2018,320(13):1360-1372.
pmid: 30285183
[6] Shahi RG, Albuquerque MTP, Münchow EA, et al. Novel bioactive tetracycline-containing electrospun polymer fibers as a potential antibacterial dental im- plant coating[J]. Odontology, 2017,105(3):354-363.
doi: 10.1007/s10266-016-0268-z pmid: 27585669
[7] Golub LM, Lee HM. Periodontal therapeutics: current host-modulation agents and future directions[J]. Periodontol 2000, 2020,82(1):186-204.
pmid: 31850625
[8] Alyousef AA, Divakar DD, Muzaheed. Chemically modified tetracyclines an emerging host modulator in chronic periodontitis patients: a randomized, double-blind, placebo-controlled, clinical trial[J]. Microb Pathog, 2017,110:279-284.
pmid: 28687322
[9] Preshaw PM. Host modulation therapy with anti-inflammatory agents[J]. Periodontol 2000, 2018,76(1):131-149.
doi: 10.1111/prd.12148 pmid: 29193331
[10] Preshaw PM, Hefti AF, Bradshaw MH. Adjunctive subantimicrobial dose doxycycline in smokers and non-smokers with chronic periodontitis[J]. J Clin Periodontol, 2005,32(6):610-616.
doi: 10.1111/j.1600-051X.2005.00728.x pmid: 15882219
[11] Vieira GHA, Messora MR, Moura JMT, et al. Sub-antimicrobial doses of doxycycline decreased bone loss related to ligature-induced periodontitis in hy-pertensive rats[J]. Arch Oral Biol, 2019,101:77-84.
doi: 10.1016/j.archoralbio.2019.03.011 pmid: 30904828
[12] Wang N, Tian X, Chen Y, et al. Low dose doxycycline decreases systemic inflammation and improves gly-cemic control, lipid profiles, and islet morphology and function in db/db mice[J]. Sci Rep, 2017,7(1):14707.
pmid: 29089617
[13] Golub LM, Elburki MS, Walker C, et al. Non-anti-bacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases[J]. Int Dent J, 2016,66(3):127-135.
doi: 10.1111/idj.12221 pmid: 27009489
[14] Swamy DN, Sanivarapu S, Moogla S, et al. Chemically modified tetracyclines: the novel host modulating agents[J]. J Indian Soc Periodontol, 2015,19(4):370-374.
pmid: 26392682
[15] Ghangurde AA, Ganji KK, Bhongade ML, et al. Role of chemically modified tetracyclines in the manage-ment of periodontal diseases: a review[J]. Drug Res (Stuttg), 2017,67(5):258-265.
[16] Ozgören O, Develioglu H, Güncü G, et al. The adjunctive effect of tenoxicam during non-surgical periodontal treatment on clinical parameters and gingival crevicular fluid levels of MMP-8 and TNF- α in patients with chronic periodontitis— randomized, double-blind clinical trial[J]. Adv Clin Exp Med, 2014,23(4):559-565.
pmid: 25166440
[17] Oduncuoglu BF, Kayar NA, Haliloglu S, et al. Effects of a cyclic NSAID regimen on levels of gingival crevicular fluid prostaglandin E2 and interleukin-1β: a 6-month randomized controlled clinical trial[J]. Niger J Clin Pract, 2018,21(5):658-666.
doi: 10.4103/njcp.njcp_221_17
[18] Etikala A, Tattan M, Askar H, et al. Effects of NSAIDs on periodontal and dental implant therapy[J]. Com-pend Contin Educ Dent, 2019,40(2):e1-e9.
[19] Dogné JM, Hanson J, Supuran C, et al. Coxibs and cardiovascular side-effects: from light to shadow[J]. Curr Pharm Des, 2006,12(8):971-975.
pmid: 16533164
[20] Hamed R, AbuRezeq A, Tarawneh O. Development of hydrogels, oleogels, and bigels as local drug de-livery systems for periodontitis[J]. Drug Dev Ind Pharm, 2018,44(9):1488-1497.
pmid: 29669437
[21] Akram Z, Abduljabbar T, Kellesarian SV, et al. Efficacy of bisphosphonate as an adjunct to nonsurgical periodontal therapy in the management of perio-dontal disease: a systematic review[J]. Br J Clin Pharmacol, 2017,83(3):444-454.
pmid: 27718252
[22] Üstün K, Erciyas K, Kısacık B, et al. Host modula-tion in rheumatoid arthritis patients with TNF blo-ckers significantly decreases biochemical parameters in periodontitis[J]. Inflammation, 2013,36(5):1171-1177.
doi: 10.1007/s10753-013-9652-9 pmid: 23649513
[23] Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology[J]. Nature, 2014,510(7503):92-101.
doi: 10.1038/nature13479 pmid: 24899309
[24] van Dyke TE. Pro-resolving mediators in the regula-tion of periodontal disease[J]. Mol Aspects Med, 2017,58:21-36.
pmid: 28483532
[25] van Dyke TE, Hasturk H, Kantarci A, et al. Prore-solving nanomedicines activate bone regeneration in periodontitis[J]. J Dent Res, 2015,94(1):148-156.
pmid: 25389003
[26] Elwakeel NM, Hazaa HH. Effect of omega 3 fatty acids plus low-dose aspirin on both clinical and bio-chemical profiles of patients with chronic periodon-titis and type 2 diabetes: a randomized double blind placebo-controlled study[J]. J Periodont Res, 2015,50(6):721-729.
[27] Cantley MD, Bartold PM, Marino V, et al. Histone deacetylase inhibitors and periodontal bone loss[J]. J Periodont Res, 2011,46(6):697-703.
[28] Qin HT, Li HQ, Liu F. Selective histone deacetylase small molecule inhibitors: recent progress and pers-pectives[J]. Expert Opin Ther Pat, 2017,27(5):621-636.
pmid: 28033734
[29] Yang H, Wen Q, Xue J, et al. Alveolar bone re-generation potential of a traditional Chinese medicine, Bu-Shen-Gu-Chi-Wan, in experimental periodontitis[J]. J Periodont Res, 2014,49(3):382-389.
[30] 吕宗凯, 郑杨灿, 杨映阳, 等. 补肾固齿丸治疗牙周炎的Meta分析[J]. 中华口腔医学研究杂志(电子版), 2015,9(4):308-312.
Lü ZK, Zheng YC, Yang YY, et al. Effects of bushen-guchiwan on treatment of perio-dontitis: a meta an-alysis[J]. Chin J Stomatol Res (Electron Ed), 2015,9(4):308-312.
[31] Curylofo-Zotti FA, Elburki MS, Oliveira PA, et al. Differential effects of natural curcumin and che-mically modified curcumin on inflammation and bone resorption in model of experimental periodontitis[J]. Arch Oral Biol, 2018,91:42-50.
pmid: 29669267
[32] Corrêa MG, Pires PR, Ribeiro FV, et al. Systemic treatment with resveratrol reduces the progression of experimental periodontitis and arthritis in rats[J]. PLoS One, 2018,13(10):e0204414.
doi: 10.1371/journal.pone.0204414 pmid: 30281626
[33] Sheridan RA, Wang HL, Eber R, et al. Systemic chemotherapeutic agents as adjunctive periodontal therapy: a narrative review and suggested clinical recommendations[J]. J Int Acad Periodontol, 2015,17(4):123-134.
pmid: 26727151
[34] Papapanou PN, Sanz M, Buduneli N, et al. Perio-dontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of perio-dontal and peri-implant diseases and conditions[J]. J Periodontol, 2018,89(Suppl 1):S173-S182.
[1] Cheng Yifan,Qin Xu,Jiang Ming,Zhu Guang-xun.. Research progress on innate lymphoid cells in periodontal diseases [J]. Int J Stomatol, 2023, 50(1): 32-36.
[2] Jia Leming,Jia Xiaoyue,Yang Ran,Zhou Xuedong,Xu Xin. Progress on the application of probiotics in the management of periodontal diseases [J]. Int J Stomatol, 2020, 47(5): 515-521.
[3] Liu Lin,Zhou Jieyu,Wu Yafei,Zhao Lei. Application of probiotic ecological regulation in prevention and treatment of periodontal diseases [J]. Int J Stomatol, 2020, 47(2): 131-137.
[4] Chen Yanyan,Peng Xian,Zhou Xuedong,Cheng Lei. Application of quantitative light-induced fluorescence in the clinical treatment of caries and periodontal diseases [J]. Int J Stomatol, 2019, 46(6): 699-704.
[5] Liu Man1, Meng Yao2, Wu Min1, Ye Lirong1, Zhang Qiang1, Wang Jindong1.. Relationship between periodontal disease and gestational diabetes mellitus [J]. Inter J Stomatol, 2015, 42(1): 19-21.
[6] Zhou Qiao, Yang Jingmei, Xu Yi. Lipoxins and their role in the resolution of periodontitis [J]. Inter J Stomatol, 2014, 41(5): 613-616.
[7] Li Qian1, Pan Yaping1,2.. Relationship between survivin and oral diseases [J]. Inter J Stomatol, 2013, 40(5): 674-677.
[8] Huang Jing, Liang Jingping.. Research progress on gingival crevicular fluid in patients with diabetes mellitus and periodontal diseases [J]. Inter J Stomatol, 2013, 40(4): 519-522.
[9] Zhang Gang, Tan Yinghui.. Series study of periodontal diseases under highland environment [J]. Inter J Stomatol, 2013, 40(2): 141-143.
[10] Lu Sixian, Wang Qing.. Research progress on Treponema denticola [J]. Inter J Stomatol, 2013, 40(1): 121-124.
[11] Zhao Danfeng, Gong Qimei, Ling Junqi.. Migration inhibitory factor and effect of its on periodontal diseases [J]. Inter J Stomatol, 2012, 39(1): 110-112.
[12] HOU Hai-juan1, ZHANG Jie1, HUANG Ping2.. Research progress on nitric oxide synthase gene polymorphisms on systemic diseases and periodontitis [J]. Inter J Stomatol, 2011, 38(2): 200-203.
[13] WU Juan, SUN Wei-bin. Porphyromonas gingivalis and atherosclerosis [J]. Inter J Stomatol, 2009, 36(2): 201-201~204.
[14] LIU Zong- xia, LI Shu.. The application of micro- computed tomogr aphy on per iodontology [J]. Inter J Stomatol, 2007, 34(06): 430-432.
[15] QI Liu- ying, FU Yun.. The role of advanced glycation end products in per iodontal diseases [J]. Inter J Stomatol, 2007, 34(06): 433-436.
Full text



[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 458 -460 .
[8] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 452 -454 .
[9] . [J]. Inter J Stomatol, 2008, 35(S1): .
[10] . [J]. Inter J Stomatol, 2008, 35(S1): .